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Abstract
Background: Anorexia nervosa is characterized by a severe restriction of caloric intake, low body weight, fear of
gaining weight or of becoming fat, and disturbance of body image. Pathogenesis of the disorder may include
genetic predisposition, hormonal changes and a combination of environmental, psychosocial, and cultural factors.
Cancer is the second leading cause of death worldwide. At present, no systematic reviews and meta-analyses have
evaluated the risk of cancer in people with anorexia nervosa. The objective of this study will be to evaluate the
association between anorexia nervosa and the risk of developing or dying from cancer.
Methods/design: This study protocol is part of a systematic collection and assessment of multiple systematic reviews
and meta-analyses (umbrella review) evaluating the association of cancer and multiple central nervous system disorders.
We designed a specific protocol for a new systematic review and meta-analysis of observational studies of anorexia
nervosa with risk of developing or dying from any cancer. Data sources will be PubMed, Embase, Scopus, Web of Science,
and manual screening of references. Observational studies (case–control and cohort) in humans that examined the
association between anorexia nervosa and risk of developing or dying from cancer will be sought. The primary outcomes
will be cancer incidence and cancer mortality in association with anorexia nervosa. Secondary outcomes will be site-
specific cancer incidence and mortality, respectively. Screening of abstracts and full texts, and data abstraction will be
performed by two team members independently. Conflicts at all levels of screening and abstraction will be resolved
through discussion. The quality of studies will be assessed by using the Ottawa-Newcastle scale by two team members
independently. Random effects models will be conducted where appropriate. Subgroup and additional analyses will be
conducted to explore the potential sources of heterogeneity. The World Cancer Research Fund (WCRF)/American Institute
for Cancer Research (AICR) criteria and the Grading of Recommendations Assessment, Development and Evaluation
(GRADE) approach will be used for determining the quality of evidence for cancer outcomes.
Discussion: Findings from this systematic review will inform an ongoing umbrella review on cancer and central nervous
system disorders. Our systematic review and meta-analysis of observational studies will establish the extent of the
epidemiological evidence underlying the association between anorexia nervosa and cancer.
Systematic review registration: PROSPERO CRD42017067462.
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Background
Anorexia nervosa is a mental disorder characterized by a
severe restriction of caloric intake, a significantly low
body weight for the developmental stage, an intense fear
of gaining weight or of becoming fat, and a severe
disturbance of body image. Pathogenesis of the disorder
may include genetic predisposition, hormonal changes,
and a combination of environmental, psychosocial, and
cultural factors [1–3]. Anorexia nervosa can affect
people of all ages and genders, and have been reported
worldwide both in high income and low-middle income
regions [4–6]. Most recent burden of disease estimates
revealed 2.9 million people with anorexia nervosa
(representing 653,019 disability-adjusted life years lost)
around the world [5, 6]. The disorder is more prevalent
among adolescent and young women; however, young
men may also be affected [5]. Although most patients
eventually recover, anorexia nervosa can blight young lives
and distort development [7–10].
Cancer is the second leading cause of death worldwide
[11, 12], with over 8.8 million deaths in 2015 [12]. There
is evidence suggesting that excess body weight is a risk
factor for several cancers. For example, a recent
umbrella review of 204 meta-analyses [13] found strong
evidence for the association between body mass index
and cancers of digestive organs (esophageal adenocarcin-
oma and cancers of the colorectum, biliary tract system,
and pancreas), hormone-related cancers (such as breast
cancer in women), endometrial cancer, kidney cancer,
and multiple myeloma; but also between adiposity and
the risk of colorectal cancer, gallbladder cancer, gastric
cardia cancer, ovarian cancer, and multiple myeloma
[13]. The underlying mechanisms between excess body
weight and cancer are complex and are not yet fully
understood. Excess body weight and adiposity might
affect immune system function and inflammatory
processes, levels of certain hormones (such as insulin
and estrogen), factors that regulate cell growth (such as
insulin-like growth factor-1 [IGF-1]), and proteins that
influence how the body uses certain hormones (such as
sex hormone-binding globulin), among others [14–16].
Research on how losing body weight might lower the
risk of developing cancer is limited. Energy restriction
(or calorie restriction) has been found to be protective
against the development of cancer in experimental
animal studies [17–20]. Energy restriction is difficult to
study in human populations. Anorexia nervosa, an
excessive form of calorie restriction associated with
pathological weight loss, has been proposed as a
biomarker of energy restriction [21, 22]. Several
epidemiological studies [22–25] have evaluated whether
there exists a general reduction in cancer development
among patients with anorexia nervosa (the so-called,
“energy-restriction hypothesis” [26]). For example, a
retrospective cohort study by Mellemkjaer et al. [22]
suggested a potential reduction, but not statistically
significant, in cancer incidence among women with an-
orexia nervosa compared with the general population
(standardized incidence ratio [SIR] = 0.80; 95% confi-
dence interval [CI] 0.52–1.18). In another retrospective
cohort study, Michels and Ekbom [23] reported that
women hospitalized for anorexia nervosa were associ-
ated with a lower incidence of breast cancer compared
to the general population (SIR = 0.47; 95% CI 0.19–0.97),
with a larger effect among parous women (SIR = 0.24;
95% CI 0.03–0.87). However, a recent observational
study assessing the risk of cancer among people with
anorexia nervosa has suggested that the potential associ-
ations in humans remain controversial [27].
At present, no systematic reviews and meta-analyses
have evaluated the epidemiological evidence examining
the association between anorexia nervosa and cancer.
To better understand the body of the evidence, we will
conduct a systematic review and meta-analysis of obser-
vational studies in order to synthesize and evaluate the
validity of the association between anorexia nervosa and
the risk of developing or dying from cancer.
Methods
Protocol
This study protocol is part of an ambitious ongoing
umbrella review (a systematic collection and assess-
ment of multiple systematic reviews and meta-
analyses) into the association of cancer and multiple
central nervous system disorders [28]. To our know-
ledge, no previous systematic reviews and meta-
analyses have evaluated the risk of developing or
dying from cancer in anorexia nervosa. For this rea-
son, we have designed a specific protocol for a new
systematic review and meta-analysis. The present
protocol has been registered within the PROSPERO
database (registration number: CRD42017067462) and
is being reported in accordance with the reporting
guidance provided in the Meta-analysis Of Observa-
tional Studies in Epidemiology (MOOSE) reporting
guideline [29] and the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses Protocols
(PRISMA-P) statement [30, 31] (see PRISMA-P checklist
in Additional file 1).
Ethics
No ethical approval is required for the performance of
this work.
Search methods
We will systematically search, from inception, PubMed/
MEDLINE, EMBASE, SCOPUS, and Web of Science to
identify observational studies examining association
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between cancer and anorexia nervosa. A date restriction
will not be imposed. The final electronic search
strategies will be defined by a senior information
specialist (AA-A) and by a clinical epidemiologist
(FC-L). Keywords related to anorexia nervosa, cancer,
and epidemiological studies will be used. A draft search
strategy for PubMed/MEDLINE database has been
included in Additional file 2. The reference lists of
examined full-text papers will be scrutinized for
additional relevant publications. We will also contact
authors of primary publications and/or collaborators to
check if they are aware of any studies we may have
missed. There will be no restriction by language of
publication, and we will arrange for translation where
necessary.
Eligibility criteria
Studies will be selected according to the following criteria:
study design, participants (exposure), comparator(s) or
control group, and outcome(s) of interest.
Study design: eligible studies will be observational
studies reporting study specific data for cancer outcomes
in people with anorexia nervosa. Prospective cohort
studies, retrospective cohort studies (also known as
historical cohort studies), and case–control studies will
be included. Randomized controlled trials will be
unavailable for our research question. We will exclude
studies in which anorexia nervosa is not the exposure of
interest, and cancer is not reported as the outcome of
interest. Observational studies not presenting study
specific data (e.g., relative risks, 95% confidence
intervals, numbers of cases/population, observed and
expected cases) or sufficient data for an outcome
measure to be calculated will be also excluded. There
will be no restriction by study setting.
Participants (exposure): index subjects will be patients
with anorexia nervosa (regardless of age or sex). We will
use investigator-reported definitions (according to
accepted diagnostic criteria such as the International
Classification of Diseases [ICD] or the Diagnostic and
Statistical Manual of Mental Disorders [DSM] criteria:
ICD-9: 307.1, 307.54; ICD-10: F50.0-F50.1). Exclusion
criteria: animals, in vitro, and in vivo experiments.
Comparator(s) or control group: the comparator group
will be based on subjects with no history of anorexia
nervosa (e.g., the general population, the community,
unexposed outpatient, or hospital-based controls).
Outcome(s): the primary outcomes will be cancer inci-
dence and cancer mortality (all malignant neoplasms;
ICD-9: 140–209; ICD-10: C00-C97) in association with
anorexia nervosa. Given the varied biology of cancers,
the risk of incident site-specific cancers, and the risk of
fatal site-specific cancers will be explored as secondary
outcomes. Site-specific cancers will be defined in groups
that include ICD codes pertaining to neoplasms [11]
(see Additional file 3).
Screening and selection procedure
Two reviewers will screen all articles identified from the
search independently. First, titles and abstracts of
articles returned from initial searches will be screened
based on the eligibility criteria outlined above. Second,
full texts will be examined in detail and screened for
eligibility. Third, references of all considered articles will
be hand-searched to identify any relevant report missed
in the search strategy by two reviewers independently.
Any disagreement between reviewers will be resolved by
discussion to meet a consensus.
Data collection process
From each eligible observational study, two reviewers will
independently extract information on first author, year of
publication, epidemiological design (cohort or case–con-
trol, prospective, or retrospective), country of study,
follow-up period, setting (mixed, inpatient, outpatient, or
community), coverage (multi-center or single center
study), general characteristics of participants (age, sex,
ethnicity, and parity status), sample size, the outcomes of
interest (including definitions and confounding factors
that were taken into consideration), the number of cases
and controls (in case–control studies) or the number of
cases and population participants (in cohort studies) and/
or the maximally adjusted relative risk (reported as odds
ratio for case–control studies and hazard ratio or stan-
dardized incidence/mortality ratio for cohort studies), and
95% confidence intervals. We will use pre-designed forms
that will be piloted initially on a small number of included
reviews and observational studies. We will also contact
authors of primary publications and/or collaborators for
missing outcome data or unclear information.
Quality and risk of bias assessment
The methodological quality and bias of primary epi-
demiological studies will be evaluated using the
Newcastle-Ottawa scale (NOS) for observational studies
[32]. Using the NOS tool, each study is judged on eight
items, categorized into three groups: the selection of the
study groups, the comparability of the groups, and the
ascertainment of either the exposure or outcome of
interest for case–control or cohort studies, respectively.
Stars are awarded for each item, and the highest quality
(low risk of bias) studies are awarded up to nine stars.
We will consider studies with 0–3, 4–6, and 7–9 stars to
represent low, moderate, and high quality, respectively.
The quality (risk of bias) for each observational study
will be independently assessed by two reviewers.
Discrepant scores will be resolved by discussion and
consensus.
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Methods for evidence synthesis
The data from each paper (e.g., population, study
characteristics, outcomes, and findings) will be used to
build evidence tables. Data from primary observational
studies will be used to perform random-effects meta-
analyses. We will estimate the summary effect size and
its 95% confidence interval using the inverse variance
method based on the DerSimonian and Laird random
effects model [33]. The random-effects model is selected
a priori to synthesize the epidemiological data, as it
considers both within-study and between-study variation
by incorporating the heterogeneity of effects into the
overall analyses. We will evaluate heterogeneity by
estimating the variance between studies using Cochran’s
Q test [34] and I2 statistic [35]. The Cochran’s Q test is
obtained by the weighted sum of the squared differences
of the observed effect in each study minus the fixed
summary effect. The I2 statistic is the ratio of variance
between studies over the sum of the variances within
and between studies, and ranges between 0 and 100%
(with values of 0–25% and 75–100% taken to indicate
low and considerable heterogeneity, respectively). In
addition, we will calculate the 95% prediction interval
[36, 37], which further accounts for between-study het-
erogeneity and evaluates the uncertainty for the effect
that would be expected in a new observational study.
We will apply a set of criteria to conclude whether the
evidence for a cancer outcome may be considered
convincing, probable, limited-suggestive, limited-not
conclusive, or unlikely. As described elsewhere [28], we will
follow the Global Burden of Disease Study approach based
on World Cancer Research Fund (WCRF)/American
Institute for Cancer Research (AICR) criteria for grading
the quality of evidence [38–40]. “Convincing evidence”
consists of biologically plausible associations between
exposure and outcome based on multiple epidemiological
studies in different populations. Evidentiary studies must be
substantial, include prospective observational studies, and
where relevant, epidemiological studies of sufficient size,
duration, and quality and showing consistent effects. A con-
vincing relationship should be robust enough to be highly
unlikely to be modified in the foreseeable future as new evi-
dence accumulates. “Probable evidence” is similarly based
on epidemiological studies with consistent associations
between exposure and outcome but with existing
shortcomings, such as insufficient prospective observational
studies available. “Limited-suggestive evidence” represents
too limited evidence to conclude on a probable or
convincing causal association, but where there is evidence
suggestive of a direction of effect. “Limited-not conclusive
evidence” consists of information that is so limited that no
firm conclusion can be made for several reasons (e.g., the
evidence might be limited by the amount of evidence in
terms of the number of studies available, by inconsistency
of direction of effect, by poor quality of studies, or by any
combination of these factors). “Substantial effect on risk
unlikely” consists of evidence strong enough to support a
judgment that a particular exposure is unlikely to have a
substantial causal relation to a cancer outcome. The
evidence should be robust enough to be unlikely to be
modified in the foreseeable future as new evidence
accumulates [40]. We will also use the Grading of
Recommendations Assessment, Development, and
Evaluation (GRADE) methodology for evaluating the qual-
ity of evidence for each outcome [41–43]. For purposes of
systematic reviews, the GRADE approach defines the qual-
ity of a body of evidence as the extent to which one can be
confident that an estimate of effect or association is close to
the quantity of specific interest. Using GRADE, the quality
of a body of evidence involves consideration of within-
study risk of bias (methodological quality), directness of
evidence, heterogeneity, precision of effect estimates, and
risk of small study effects (sometimes called “publication
bias”) [41–43]. GRADE rating will be adjudicated as high
(further research is very unlikely to change our confidence
in the estimate of effect), moderate (further research is
likely to have an important impact on our confidence in the
estimate of effect and may change the estimate), low (fur-
ther research is very likely to have an important impact on
our confidence in the estimate of effect and is likely to
change the estimate), or very low (very uncertain about the
estimate of effect) [41, 44].
Additional analyses
If sufficient studies are identified, potential sources of
heterogeneity will be investigated further by subgroup or
meta-regression analyses according to baseline charac-
teristics and methodological factors [28]. We plan to
conduct subgroup analyses by sex (men or women), age
(e.g., at first diagnosis of anorexia nervosa), study design
(cohort or case–control; prospective, or retrospective),
follow-up (0–1, >1–5, or >5 years), setting (mixed, in-
patient, outpatient, or community), ethnicity (e.g., Asian
or non-Asian), population-based (yes or no), country
economic status (developed or developing countries
according to International Monetary Fund), year of
publication (before 2000 or in 2000 and after), study
quality (high or low-moderate risk of bias), adjustment
for confounding variables (age, sex or other), and sample
size (<500, 500–1000 or >1000 participants). If sufficient
information is identified, we will conduct subgroup
analyses or meta-regression analyses for cancer types
according to relationship with smoking (smoking-related
cancer sites or other cancer sites) or sex hormones
(cancers occurring in hormone-sensitive tissues such as
breast, ovary, uterine endometrium, prostate and colo-
rectal, where sex hormones exert an important role in
cancer etiopathogenesis and progression) [23, 45, 46]
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(see Additional file 2). We will conduct a specific sub-
group analysis among women based on parity status
(parous or nulliparous women) [23, 24]. If sufficient
studies are identified, we will perform cumulative meta-
analyses in the order of publication year showing the
consistency of evidence over time [47, 48]. Small study
effects will be assessed by inspection of the funnel plots
for asymmetry and with Egger’s test [49] and Begg’s test
[50], with the results considered to indicate potential
small study effects when P < 0.10.
Software considerations
All analyses will be conducted in Stata version 13 or
higher (StataCorp LP, College Station, Texas, USA) using
the metan (for fixed and random effects meta-analysis),
metareg (for meta-regression analysis), metacum (for
cumulative meta-analysis), and metabias and metafunnel
(for small study effects analysis) [51].
Discussion
The systematic review presented in this protocol will
inform an ongoing umbrella review and meta-analysis of
observational studies on cancer and central nervous
system disorders [28]. This systematic review will
establish the extent of the epidemiological evidence
underlying the association between anorexia nervosa
and the risk of developing or dying from cancer, in a
reproducible and rigorous way. The systematic review
and meta-analysis presented in this protocol will be
reported in accordance with the reporting guidance
provided in the PRISMA statement [52] and the
MOOSE reporting guideline [29]. Any amendments or
modifications made in the protocol will be outlined and
reported in the final paper.
Direct and inverse cancer comorbidity could be a
relevant model to investigate common or related pathways
or processes and test new therapies and prevention pro-
grams, but, most importantly, to understand why certain
people might potentially be protected from the malig-
nancy [25, 53, 54]. In this context, understanding the
complex connections between anorexia nervosa and can-
cer might be important for clinical research and practice.
There are several strengths and limitations of our
planned methods. We will comprehensively evaluate
epidemiological data characterizing the associations
between anorexia nervosa and cancer, exploring the
extent of heterogeneity and bias in observational studies.
We have planned assessments of meta-bias and strength
of evidence statements. We anticipate that we will
identify knowledge gaps to be filled by new research
considering that some outcomes will be poorly covered
in the biomedical literature. A key challenge is that
based on knowledge from previous reviews on cancer
and central nervous system disorders [54–57], we
anticipate identifying studies using different study
designs, populations, durations, and with a variable
quality of reporting methods and results.
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